WHO ICTRP trial
IFN-beta twice a daily/Ribavirin combination therapy following…
JPRN-UMIN000003549 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000003549 |
|---|---|
| Public title | IFN-beta twice a daily/Ribavirin combination therapy following PEG-IFN-alfa/Ribavirin therapy for chronic hepatitis C patients: efficacy and safety |
| Scientific title | IFN-beta twice a daily/Ribavirin combination therapy following PEG-IFN-alfa/Ribavirin therapy for chronic hepatitis C patients: efficacy and safety - IFN-beta twice a daily/Ribavirin combination therapy following PEG-IFN-alfa/Ribavirin therapy for chronic hepatitis C patients |
| Primary sponsor | kanazawa university |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | chronic hepatitis C |
| Interventions | IFN-beta twice a daily/Ribavirin therapy following Peg-IFN-alfa/Ribavirin therapy |
| Registration date | Jan 6, 2010 |
| Target size | 40 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: